JCOGP
Journal of Controversies in Obstetrics & Gynecology and Pediatrics

As of January 2023, our "Journal of Controversies Obstetrics & Gynecology and Pediatrics" has been published under the Medihealth Academy to publish all articles, reviews and case reports on Pediatrics, especially in the field of Obstetrics and Gynecology. In order to facilitate the citation of the articles, to take our place in internationally respected indexes and to reach a wider readership, we will pay attention to the fact that our article language is only English in terms of acceptance.

eISSN: 2980-0579
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Evaluation of fetomaternal outcomes and serum analytes in placenta previa and associated placenta accreta spectrum
Abstract
Aims: Evaluation of fetomaternal outcomes and serum analytes values in patients with placenta previa and associated placenta accreta spectrum ( PAS).
Methods: The study comprised 160 patients, of whom 74 (46.3%) had placenta previa, 28 (17.5%) had PAS, and 58 (36.3%) were pregnant women in a healthy condition. The diagnosis was suspected by ultrasound examination and confirmed by the intraoperative findings and the pathology report. Demographic and obstetric characteristics data of the pregnant women, maternal and fetal outcomes, screening tests for the first and second trimester results of serum analysis were obtained retrospectively from the hospital records. The significance threshold was set at p<0.05 using the IBM SPSS.25 software.
Results: The mean age was significantly higher in the previa and PAS groups. The groups differed significantly in terms of the history of prior cesarean deliveries and gestational age at delivery. The PAS group had the lowest APGAR score and the lowest newborn weight (p<.001). Compared to the PAS group, the previa group's PAPP-A (pregnancy associated plasma protein-A) Mom value was considerably greater (p=.008). The AFP (alpha-fetoprotein) Mom value was significantly higher in the group of healthy pregnant women than in the group of previa (p=.015). Compared to the previa (p=.008) and PAS (p=.024) groups, the healthy pregnant group's UE3 (Unconjugated Estriol-3) Mom value was much higher.
Conclusion: Although the obstetric, fetal and maternal outcomes in our study were consistent with the literature, the serum analysis results were not.

Keywords : Placenta previa, PAS, PAPP-A, AFP, UE3

Download Article


1. Faiz AS, Ananth CV. Etiology and risk factors for placenta previa: an overview and meta-analysis of observational studies. J Matern Fetal Neonatal Med. 2003;13(3):175-190. doi:10.1080/jmf.13.3.175.190
2. Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: twenty-year analysis. Am J Obstet Gynecol. 2005;192(5):1458-1461. doi:10.1016/j.ajog.2004.12.074
3. Tikkanen M, H&auml;m&auml;l&auml;inen E, Nuutila M, Paavonen J, Ylikorkala O, Hiilesmaa V. Elevated maternal second-trimester serum alpha-fetoprotein as a risk factor for placental abruption. Prenat Diagn. 2007; 27(3):240-243. doi:10.1002/pd.1654
4. Cresswell JA, Ronsmans C, Calvert C, Filippi V. Prevalence of placenta praevia by world region: a systematic review and meta-analysis. Trop Med Int Health. 2013;18(6):712-24. doi:10.1111/tmi.12100
5. Karami M, Jenabi E, Fereidooni B. The association of placenta previa and assisted reproductive techniques: a meta-analysis. J Matern Fetal Neonatal Med. 2018;31(14):1940-1947. doi:10.1080/14767058.2017.1332035
6. Eshkoli T, Weintraub AY, Sergienko R, Sheiner E. Placenta accreta: risk factors, perinatal outcomes, and consequences for subsequent births. Am J Obstet Gynecol. 2013;208(3):219.e1-7. doi:10.1016/j.ajog.2012.12.037
7. Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins S; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2019;146(1):20-24. doi:10. 1002/ijgo.12761
8. American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric care consensus no. 7: placenta accreta spectrum. Obstet Gynecol. 2018;132(6):e259-e275. doi:10.1097/AOG.0000000000002983
9. Jauniaux E, Alfirevic Z, Bhide AG, et al. Placenta praevia and placenta accreta: diagnosis and management: green-top guideline no. 27a. BJOG Int J Obstet Gynaecol. 2019;126:e1-e48. doi:10.1111/14-71-0528.15306
10. Collins SL, Alemdar B, van Beekhuizen HJ, et al. Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta. Am J Obstet Gynecol. 2019;220(6):511-526. doi:10. 1016/j.ajog.2019.02.054
11. Silver RM, Landon MB, Rouse DJ, et al. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol. 2006;107(6):1226-1232. doi:10.1097/01.AOG. 0000219750
12. Jauniaux E, Bunce C, Gr&oslash;nbeck L, Langhoff-Roos J, Prevalence and main outcomes of placenta accreta spectrum: a systematic review and meta-analysis. Am J Obstet Gynecol. 2019;221(3):208-218. doi:10.1016/j.ajog.2019.01.233
13. Berezowsky A, Pardo J, Ben-Zion M, et al. Second trimester biochemical markers as possible predictors of pathological placentation: a retrospective case-control study. Fetal Diagn Ther. 2019;46(3):187-192. doi:10.1159/000492829
14. Rosenberg T, Pariente G, Sergienko R, Wiznitzer A, Sheiner E. Critical analysis of risk factors and outcome of placenta previa. Arch Gynecol Obstet. 2011;284:47-51. doi:10.1007/s00404-010-1598-7
15. Zhang L, Li P, He GL, et al. Value of prenatal diagnosis of placenta previa with placenta incret by transabdominal color Doppler ultrasound. Zhonghua Fu Chan Ke Za Zhi. 2006;41:799-802.
16. Daskalakis G, Simou M, Zacharakis D, et al. Impact of placenta previa on obstetric outcome. Int J Gynaecol Obstet. 2011;114(3):238-241. doi:10. 1016/j.ijgo.2011.03.012
17. Marshall NE, Fu R, Guise JM. Impact of multiple caesarean deliveries on maternal morbidity: a systematic review. Am J Obstet Gynecol. 2011; 205(3):262.e1-262.e2628. doi:10.1016/j.ajog.2011.06.035
18. Naeye RL. Maternal age, obstetric complications, and thoutcome of pregnancy. Obstet Gynecol. 1983;61(2):210-216.
19. Timor-Tritsch IE, Monteagudo A. Unforeseen consequences of the increasing rate of cesarean deliveries: early placenta accreta and cesarean scar pregnancy. A review. Am J Obstet Gynecol. 2012;207(1):14-29. doi:10.1016/j.ajog.2012.03.007
20. Breen JL, Neubecker R, Gregori CA, Franklin JE. Placenta accreta, increta, and percreta. A survey of 40 cases. Obstet Gynecol. 1977;49(1): 43-47.
21. American College of Obstetricians and Gynecologists&rsquo; Committee on Obstetric Practice, Society for Maternal-Fetal Medicine. Medically Indicated late-preterm and early-term deliveries: ACOG Committee Opinion, Number 831. Obstet Gynecol. 2021;138(1):e35-e39. doi:10.1097/AOG.0000000000004447
22. American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 7: Placenta Accreta Spectrum. Obstet Gynecol. 2018;132(6):e259-e275. doi:10.1097/AOG.0000000000002983
23. Ogawa K, Jwa SC, Morisaki N, Sago H. Risk factors and clinical outcomes for placenta accreta spectrum with or without placenta previa. Arch Gynecol Obstet. 2022;305(3):607-615. doi:10.1007/s00404-021-06189-2
24. Findik FM. Factors associated with placenta previa: a retrospective, single-center study in Turkey. Med Sci Monit. 2022;28:e938023. doi:10. 12659/MSM.938023
25. Dreux S, Salomon LJ, Muller F, Goffinet F, Oury JF, Sentilhes L; ABA Study Group. Second- trimester maternal serum markers and placenta accreta. Prenat Diagn. 2012; 32(10):1010-1012. doi:10.1002/pd.3932
26. Hung TH, Shau WY, Hsieh CC, Chiu TH, Hsu JJ, Hsieh TT. Risk factors for placenta accreta. Obstet Gynecol. 1999;93(4):545-550. doi:10.1016/s0029-7844(98)00460-8
27. Kupferminc MJ, Tamura RK, Wigton TR, Glassenberg R, Socol ML. Placenta accreta is associated with elevated maternal serum alpha-fetoprotein. Obstet Gynecol. 1993;82(2):266-269.
28. Yaron Y, Cherry M, Kramer RL, at al. Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol. 1999;181(4):968-974. doi:10.1016/s0002-9378(99)70334-0
29. Wenstrom KD, Owen J, Boots LR, DuBard MB. Elevated second-trimester human chorionic gonadotropin levels in association with poor pregnancy outcome. Am J Obstet Gynecol. 1994;171(4):1038-1041. doi:10.1016/0002-9378(94)90030-2
Article available in :
Volume 3, Issue 3, 2025
Page : 51-55
https://doi.org/10.51271/JCOGP-0049
Article Information
Received : 30 Oca 2025
Accepted : 17 Şub 2025
Published : 07 Tem 2025
Corresponding Author :

Neval Çayönü Kahraman: Department of Perinatology, Ankara Etlik City Hospital, Ankara, Turkiye

[email protected]
Citation : Çayönü Kahraman N, Dağdeviren G, Biltekin S, Özkan HD, Vanlı Tonyalı N, Çağlar AT. Evaluation of fetomaternal outcomes and serum analytes in placenta previa and associated placenta accreta spectrum. J Controv Obstetr Gynecol Ped. 2025;3(3):51-55.

Read: 271
Download : 264
Cited: 0
_Footer